Investing.com - Financial Markets Worldwide

Imfinzi by AstraZeneca gets US approval for bladder cancer treatment

Published 31/03/2025, 07:40
© Reuters.
AZN
1.39%

Investing.com -- AstraZeneca (NASDAQ:AZN)’s drug, Imfinzi, has received approval in the United States for the treatment of adult patients suffering from muscle-invasive bladder cancer, according to an official statement.

The approval allows the use of Imfinzi in combination with two other drugs, gemcitabine and cisplatin, as a neoadjuvant treatment. Following this, Imfinzi will be used as an adjuvant monotherapy after a surgical procedure known as radical cystectomy.

The treatment regimen involving Imfinzi has shown to reduce the risk of death by 25% compared to the use of neoadjuvant chemotherapy with radical cystectomy alone.

This development marks a significant step forward in the treatment options available for muscle-invasive bladder cancer patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.